{"id":"NCT02991118","sponsor":"Esperion Therapeutics, Inc.","briefTitle":"Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk","officialTitle":"A Long-term, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk Not Adequately Controlled by Their Lipid-Modifying Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-18","primaryCompletion":"2018-08-22","completion":"2018-08-22","firstPosted":"2016-12-13","resultsPosted":"2020-04-27","lastUpdate":"2020-04-27"},"enrollment":779,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia","Atherosclerotic Cardiovascular Disease"],"interventions":[{"type":"DRUG","name":"bempedoic acid","otherNames":["ETC-1002"]},{"type":"DRUG","name":"placebo","otherNames":["placebo control"]}],"arms":[{"label":"bempedoic acid","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to see if bemedoic acid (ETC-1002) is effective versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol not adequately controlled by their current therapy.","primaryOutcome":{"measure":"Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)","timeFrame":"Baseline; Week 12","effectByArm":[{"arm":"Placebo","deltaMin":2.35,"sd":1.446},{"arm":"Bempedoic Acid","deltaMin":-15.07,"sd":1.073}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":["31714986","27892461","21067804","26039521","23461430","24222016","35916348","32609313"],"seeAlso":["http://www.who.int/mediacentre/factsheets/fs317/en/","https://thefhfoundation.org/about-fh/what-is-fh/"]},"adverseEventsSummary":{"seriousAny":{"events":48,"n":257},"commonTop":["Nasopharyngitis","Urinary tract infection","Upper respiratory tract infection","Hyperuricaemia","Arthralgia"]}}